Memantine Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder: An Open-Label Trial
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Background: Data from the fields of genetics, neuroimaging, and animal studies, along with case reports and small clinical trials, point to a role for glutamatergic dysfunction in the pathophysiology of obsessive-compulsive disorder (OCD). We report on the first open-label study to test the hypothesis that memantine, a noncompetitive glutamate antagonist, will result in a clinically meaningful reduction in OCD symptoms in adults with treatment-resistant OCD. Methods: We recruited 15 adult subjects with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-defined OCD and a baseline Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) of 18 or higher, who had failed to respond to treatment with a serotonin reuptake inhibitor (SRI), given at an adequate and stable dose for at least 12 weeks. The duration of memantine treatment was 12 weeks, and the dose was gradually increased to a target of 20 mg/d. Response was defined as a 25% or greater reduction in the Y-BOCS score at study end and a Clinical Global Impression-Improvement scale rating of "much" or "very much" improved. Results: Data from 14 subjects were analyzable. Mean baseline Y-BOCS score was 27.4 (SD, 5.0). Subjects had failed an average of 2.8 (SD, 1.8) SRI trials; 6 subjects had failed augmentation with atypical antipsychotics. At study end, 6 subjects (42.9%) were responders, and response was achieved by EOW4. Responders had significantly lower baseline Y-BOCS scores (2-tailed t tests, P < 0.05, t = 2.2) and had failed fewer SRIs (P ≤ 0.05, t = 2.2). Side effects to memantine were mild and transient, and no subject withdrew from the study for an adverse event. Summary: In this open-label augmentation trial of memantine in treatment-resistant OCD, almost half the subjects had a meaningful improvement in symptoms. Our study was limited by its small size, presence of comorbidities, and lack of control. Large double-blind placebo-controlled trials are needed to further test our findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712 · cited 2×
“The primary efficacy measure was the Y-BOCS.(32) Secondary measures included the CGI-I(33) and the Montgomery-Asberg Depression Rating Scale (MADRS).”
MethodPractice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder
(2008) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.149114 · Cited by 1,028
ROSENBERG, D. R., MacMASTER, F. P., KESHAVAN, M. S., FITZGERALD, K. D., STEWART, C. M., & MOORE, G. J. (2000) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200009000-00008 · Cited by 377
Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder
Arnold, P. D., Sicard, T., Burroughs, E., Richter, M. A., & Kennedy, J. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.7.769 · Cited by 357
Glutamatergic Dysfunction in OCD
Chakrabarty, K., Bhattacharyya, S., Christopher, R., & Khanna, S. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300733 · Cited by 344
Evidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial
Coric, V., Taskiran, S., Pittenger, C., Wasylink, S., Mathalon, D. H., Valentine, G., Saksa, J., Wu, Y.-T., Gueorguieva, R., Sanacora, G., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.043 · Cited by 314 · cited 2×
“Medications that increase serotonergic neurotransmission have been the cornerstone of OCD pharmacotherapy since uncontrolled trials in the 1960s suggested that clomipramine, the tricyclic antidepressant most specific for serotonin, was efficacious.(3) Controlled trials subsequently confirmed its efficacy, but serious…”
BackgroundNeurosurgery for intractable obsessive-compulsive disorder and depression: critical issues
Greenberg, B. D., Price, L. H., Rauch, S. L., Friehs, G., Noren, G., Malone, D., Carpenter, L. L., Rezai, A. R., & Rasmussen, S. A. (2003) · Neurosurgery Clinics of North America · doi:10.1016/s1042-3680(03)00005-6 · Cited by 300
Dickel, D. E., Veenstra-VanderWeele, J., Cox, N. J., Wu, X., Fischer, D. J., Van Etten-Lee, M., Himle, J. A., Leventhal, B. L., Cook, E. H., & Hanna, G. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.7.778 · Cited by 274 · cited 1×
“More recently, 2 groups have reported a statistically significant association between OCD and a locus on chromosome 9p24 that codes for the amino acid transporter SLC1A1 (solute carrier family 1, member 1), considered important in terminating the action of glutamate and maintaining extracellular glutamate concentratio…”
BackgroundArnold, P., Rosenberg, D., Mundo, E., Tharmalingam, S., Kennedy, J., & Richter, M. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1847-1 · Cited by 202 · cited 1×
“A study of 130 families affected with OCD found a significant positive association with the N-methyl-D-aspartate (NMDA) glutamate receptor subunit GRIN2B (glutamate receptor, ionotropic, N-methyl-D-aspartate 2B).(16) Another study, however, did not find an association between OCD and 2 kainate subtype glutamate recept…”
Background
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Adjunctive lamotrigine [799,800] 2 Adjunctive memantine [622,781-783] 2”
BackgroundCampos, A. C., Moreira, F. A., Gomes, F. V., Del Bel, E. A., & Guimarães, F. S. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0389 · Cited by 475
Pittenger, C., Bloch, M. H., & Williams, K. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.006 · Cited by 426
“Aboujaoude and colleagues (Aboujaoude et al., 2009) described an open-label trial of 15 refractory OCD patients who were treated with 12 weeks of memantine augmenation; 42% were judged to be treatment responders, defined as a 25% improvement from symptom baseline.”
BackgroundRandomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept
Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., Flood, P., & Simpson, H. B. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.150 · Cited by 386
Evidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
Sani, G., Serra, G., Kotzalidis, G. D., Romano, S., Tamorri, S. M., Manfredi, G., Caloro, M., Telesforo, C. L., Caltagirone, S. S., Panaccione, I., et al. (2012) · CNS Drugs · doi:10.2165/11634390-000000000-00000 · Cited by 273
The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder
Wu, K., Hanna, G. L., Rosenberg, D. R., & Arnold, P. D. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.10.007 · Cited by 264
“It has shown efficacy as an augmenting agent in refractory OCD in several case reports (Poyurovsky et.al, 2005; Pasquini and Biondi, 2006; Hezel et al., 2009), as well as open-label trials (Feusner et al., 2009; Aboujaoude et al., 2009).”
New perspectives in glutamate and anxiety
Riaza Bermudo-Soriano, C., Perez-Rodriguez, M. M., Vaquero-Lorenzo, C., & Baca-Garcia, E. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.04.010 · Cited by 207
Fineberg, N. A., Hollander, E., Pallanti, S., Walitza, S., Grünblatt, E., Dell’Osso, B. M., Albert, U., Geller, D. A., Brakoulias, V., Janardhan Reddy, Y. C., et al. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000314 · Cited by 161
Ghaleiha, A., Entezari, N., Modabbernia, A., Najand, B., Askari, N., Tabrizi, M., Ashrafi, M., Hajiaghaee, R., & Akhondzadeh, S. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.09.015 · Cited by 152
Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors
Casarotto, P. C., Gomes, F. V., Resstel, L. B. M., & Guimarães, F. S. (2010) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32833b33c5 · Cited by 141
“…preclinical and clinical studies suggest that drugs attenuating glutamate neurotransmission, such as riluzole and memantine, could be helpful in the treatment of OCD patients (Grant et al., 2007; Aboujaoude et al., 2009) and are effective in the MBT (Egashira et al., 2008a; Iijima et al., 2010).”
BackgroundPharmacotherapy of obsessive–compulsive disorder: evidence-based treatment and beyond
Fineberg, N. A., Reghunandanan, S., Brown, A., & Pampaloni, I. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412461958 · Cited by 122
“In a 12-week, open-label trial (Aboujaoude et al., 2009), adjunctive memantine (5–20 mg) was prescribed to 15 patients who had failed to respond adequately to 12 weeks of SRI.”
MethodStewart, S. E., Mayerfeld, C., Arnold, P. D., Crane, J. R., O'Dushlaine, C., Fagerness, J. A., Yu, D., Scharf, J. M., Chan, E., Kassam, F., et al. (2013) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32137 · Cited by 102
“Multiple studies have reported symptom improvement in OCD by augmenting with glutamatemodulating agents such as riluzole [Coric et al., 2005; Grant et al., 2007] or memantine [Aboujaoude et al., 2009; Stewart et al., 2010].”
BackgroundGlutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder
Marinova, Z., Chuang, D.-M., & Fineberg, N. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170320104237 · Cited by 83
“Three small, open label trials of memantine, administered either as monotherapy or adjunctive to SRI [81-83], were also performed.”
BackgroundRossignol, D. A., & Frye, R. E. (2014) · Frontiers in Pediatrics · doi:10.3389/fped.2014.00087 · Cited by 79
Pereira, V. S., Casarotto, P. C., Hiroaki-Sato, V. A., Sartim, A. G., Guimarães, F. S., & Joca, S. R. L. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.01.008 · Cited by 66
“This is also true for obsessive–compulsive disorder (OCD), an anxiety-spectrum disorder with a poorly understood neurobiology (Andersen et al., 2010).”
Rodriguez, C. I., Kegeles, L. S., Flood, P., & Simpson, H. B. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10l06653 · Cited by 59
“decreases NMDA activity9; and (3) ketamine has been safely used in patients with depression and can relieve depressive symptoms in hours.”
BackgroundHeidari, M., Zarei, M., Hosseini, S. M. R., Taghvaei, R., Maleki, H., Tabrizi, M., Fallah, J., & Akhondzadeh, S. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000043 · Cited by 48
Investigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder
Grassi, G., Cecchelli, C., Vignozzi, L., & Pacini, S. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s255375 · Cited by 44
Barton, S., Karner, C., Salih, F., Baldwin, D. S., & Edwards, S. J. (2014) · Health Technology Assessment · doi:10.3310/hta18500 · Cited by 36
Porton, B., Greenberg, B. D., Askland, K., Serra, L. M., Gesmonde, J., Rudnick, G., Rasmussen, S. A., & Kao, H.-T. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.35 · Cited by 36
Sayyah, M., Olapour, A., Saeedabad, Y. S., Yazdan Parast, R., & Malayeri, A. (2012) · Nutrition · doi:10.1016/j.nut.2011.11.027 · Cited by 28
Metadata
- Authors
- Aboujaoude, E., Barry, J. J., & Gamel, N.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2009-02
- Volume
- 29
- Issue
- 1
- Pages
- 51-55
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W1994168324
- Cited by
- 136
- References
- 14
- FWCI
- 15.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.